It would be inaccurate to characterize GlycanAge as a startup. To fully understand GlycanAge’s roadmap, we must travel back in time by about two decades and trace the advancements of Gordan Lauc, the company’s co-founder, chief scientific officer, director of the National Centre of Scientific Excellence in Personalised Healthcare, professor of biochemistry and molecular biology at the University of Zagreb, honorary professor at the Universities of Edinburgh and King’s College London, and member of the Johns Hopkins Society of Scholars.
Dr. Lauc has been leading his team in the advancement of glycomic analysis and utilizing glycan biomarkers for precision medicine. This has resulted in the Human Glycome Project being launched in 2017.
GlycanAge is the commercialization phase of these almost two decades of study, made possible by nearly $40 million in grant funding and many late nights in the lab.
“I am thrilled to see that glycan research is finding its way to the market. After pioneering high-throughput glycomics 15 years ago we analysed glycans in over 200,000 people and identified numerous potential biomarkers that can be applied in the field of personalised preventive medicine.
“Glycans are the ultimate layer of molecular complexity, but their biomarker potential still needs to be fully translated into commercial applications that will benefit human health. GlycanAge is the global pioneer in this respect and its success will advance the entire field of glycomics.”
Gordan Lauc, co-founder, chief scientific officer, GlycanAge
Furthermore, the GlycanAge team claims that this $4.2 million seed investment, led by LAUNCHub Ventures, will allow the business to expand beyond the longevity industry and further into the possibly even more valuable diagnostics market, all while developing a distinct regulatory strategy and product pipeline.
